Skip to content

Does overweight change the pattern of lung function during the airway narrowing of asthma?

Is there a difference in lung function during bronchial challenge testing between obese and non-obese subjects with asthma?

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12606000455561
Acronym
the INCA study
Enrollment
30
Registered
2006-10-27
Start date
2006-12-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The hypothesis is that the airway narrowing of acute asthma is different depending on whether an individual is obese or non-obese. If this hypothesis is proven or refuted, it will help to aid doctors in acurately interpreting respiratory function tests.

Interventions

By testing individuals during broncho-constriction induced by airway challenge testing, we will measure lung function parameters to investigate whether obese asthmatics demonstrate the same spirometric picture compared to non-obese asthmatics. The measurements will be conducted at the begining of the challenge test, during and after bronchoconstriction has been achieved. The provocation test usually lasts half an hour and the lung function testing takes 15 mins at the beginning and end.

Sponsors

Professor Robin Taylor, principle investigator, Respiratory Research Unit, Department of Medical and Surgical Sciences, University of Otago, Dunedin New Zealand
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

A previous diagnosis of asthma (according to ATS criteria) and a positive methacholine challenge (PD20 <8 micromol if on not on corticosteroid inhalers and PD¬20 < 12 micromol if on corticosteroid inhalers).

Exclusion criteria

Pregnancy, males, smokers or ex-smokers (less than 10 pack year history and no cigarettes for in the last year), patients on oral corticosteroids, any patient with cardiac or neurological co-morbidity, any patient who has had a respiratory tract infection in the previous 6 weeks and for safety reasons, FEV1 less than 60% predicted or less than 1.5 litres at baseline, when stable.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026